GlaxoSmithKline plc Acquires Sirtris Pharmaceuticals for $720,000,000
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=97c6bb1a-59e5-4a2a-ad8e-4ee0822951e2&Preview=1
Date 4/22/2008
Company Name Sirtris Pharmaceuticals
Mailing Address 200 Technology Square Cambridge, MA 02139
Company Description Sirtris Pharmaceuticals” is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body’s natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for diseases of aging, including metabolic and neurological diseases.